Compare Stocks: BNTX, REGN, ARGX, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$867.94 +2.8%	$876.87	$631.47 ▼ $953.58	$54.30B	0.46	350,472 shs	358,792 shs
BNTX BioNTech	$92.18 +0.9%	$91.47	$79.52 ▼ $124.00	$23.31B	1.27	1.03 million shs	1.70 million shs
REGN Regeneron Pharmaceuticals	$768.58 +1.0%	$650.88	$541.00 ▼ $821.11	$81.25B	0.22	858,955 shs	532,348 shs
RVMD Revolution Medicines	$197.30 +2.0%	$174.85	$34.00 ▼ $198.30	$41.95B	1.39	3.15 million shs	1.95 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.65%	-3.18%	-10.13%	+4.58%	+22.33%
BNTX BioNTech	-0.98%	-1.19%	-6.35%	-4.10%	-16.98%
REGN Regeneron Pharmaceuticals	+0.19%	+9.42%	+16.26%	+5.49%	+33.09%
RVMD Revolution Medicines	+6.03%	+5.22%	+2.23%	+28.06%	+420.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$867.94 +2.8%	$876.87	$631.47 ▼ $953.58	$54.30B	0.46	350,472 shs	358,792 shs
BNTX BioNTech	$92.18 +0.9%	$91.47	$79.52 ▼ $124.00	$23.31B	1.27	1.03 million shs	1.70 million shs
REGN Regeneron Pharmaceuticals	$768.58 +1.0%	$650.88	$541.00 ▼ $821.11	$81.25B	0.22	858,955 shs	532,348 shs
RVMD Revolution Medicines	$197.30 +2.0%	$174.85	$34.00 ▼ $198.30	$41.95B	1.39	3.15 million shs	1.95 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.65%	-3.18%	-10.13%	+4.58%	+22.33%
BNTX BioNTech	-0.98%	-1.19%	-6.35%	-4.10%	-16.98%
REGN Regeneron Pharmaceuticals	+0.19%	+9.42%	+16.26%	+5.49%	+33.09%
RVMD Revolution Medicines	+6.03%	+5.22%	+2.23%	+28.06%	+420.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,056.89	21.77% Upside
BNTX BioNTech	2.74	Moderate Buy	$127.81	38.66% Upside
REGN Regeneron Pharmaceuticals	2.67	Moderate Buy	$797.75	3.80% Upside
RVMD Revolution Medicines	2.95	Moderate Buy	$144.67	-26.67% Downside

Current Analyst Ratings Breakdown

Latest BNTX, REGN, ARGX, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$142.00
8/5/2026	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$130.00 ➝ $125.00
8/4/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1,185.00
8/3/2026	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$700.00 ➝ $740.00
8/3/2026	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,000.00 ➝ $1,030.00
7/31/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$696.00 ➝ $737.00
7/31/2026	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$730.00 ➝ $758.00
7/31/2026	REGN Regeneron Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$750.00 ➝ $795.00
7/31/2026	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$700.00 ➝ $750.00
7/31/2026	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$769.00 ➝ $772.00
7/29/2026	REGN Regeneron Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$5.23B	10.39	$22.29 per share	38.94	$134.54 per share	6.45
BNTX BioNTech	$3.25B	7.18	$1.33 per share	69.10	$96.59 per share	0.95
REGN Regeneron Pharmaceuticals	$14.34B	5.67	$42.49 per share	18.09	$299.96 per share	2.56
RVMD Revolution Medicines	$11.58M	3,622.28	N/A	N/A	$8.44 per share	23.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	33.33	24.26	1.05	32.19%	43.59%	36.66%	N/A
BNTX BioNTech	-$1.29B	-$5.88	N/A	N/A	N/A	-44.39%	-5.30%	-4.62%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.00	17.38	1.49	27.86%	13.47%	10.34%	N/A
RVMD Revolution Medicines	-$1.13B	-$7.07	N/A	N/A	N/A	N/A	-83.22%	-59.06%	8/5/2026 (Estimated)

Latest BNTX, REGN, ARGX, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/6/2026	Q1 2026	RVMD Revolution Medicines	-$1.83	-$2.29	-$0.46	-$2.29	$2.43 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.49%	N/A	9.29%	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Latest BNTX, REGN, ARGX, and RVMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.51%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
BNTX BioNTech	0.01	8.80	8.74
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
RVMD Revolution Medicines	0.19	6.80	6.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BNTX BioNTech	15.52%
REGN Regeneron Pharmaceuticals	83.31%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BNTX BioNTech	19.20%
REGN Regeneron Pharmaceuticals	6.97%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable
RVMD Revolution Medicines	250	212.60 million	196.44 million	Optionable

BNTX, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

3 hours ago | globenewswire.com

Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - Time to Buy?

August 5 at 11:59 AM | marketbeat.com

Amundi Buys 118,493 Shares of Revolution Medicines, Inc. $RVMD

August 5 at 3:03 AM | marketbeat.com

Royal Bank of Canada Sells 131,978 Shares of Revolution Medicines, Inc. $RVMD

August 4 at 4:56 AM | marketbeat.com

The Manufacturers Life Insurance Company Decreases Position in Revolution Medicines, Inc. $RVMD

August 3 at 5:11 AM | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Sold by Defilade Capital Management L.P.

August 3 at 4:23 AM | marketbeat.com

First Trust Advisors LP Boosts Holdings in Revolution Medicines, Inc. $RVMD

August 3 at 3:35 AM | marketbeat.com

California State Teachers Retirement System Boosts Stock Position in Revolution Medicines, Inc. $RVMD

August 3 at 3:27 AM | marketbeat.com

Seven Fleet Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 2 at 6:31 AM | marketbeat.com

Perceptive Advisors LLC Purchases New Position in Revolution Medicines, Inc. $RVMD

August 2 at 6:07 AM | marketbeat.com

15,000 Shares in Revolution Medicines, Inc. $RVMD Bought by Avidity Partners Management LP

August 1, 2026 | marketbeat.com

Edgestream Partners L.P. Invests $6.74 Million in Revolution Medicines, Inc. $RVMD

July 31, 2026 | marketbeat.com

Dimensional Fund Advisors LP Sells 317,032 Shares of Revolution Medicines, Inc. $RVMD

July 31, 2026 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by Brokerages

July 31, 2026 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 31, 2026 | marketbeat.com

Janus Henderson Group PLC Has $949.54 Million Holdings in Revolution Medicines, Inc. $RVMD

July 30, 2026 | marketbeat.com

Gabelli Funds LLC Purchases Shares of 15,750 Revolution Medicines, Inc. $RVMD

July 30, 2026 | marketbeat.com

Bank of Nova Scotia Decreases Position in Revolution Medicines, Inc. $RVMD

July 30, 2026 | marketbeat.com

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

July 29, 2026 | globenewswire.com

Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Readystate Asset Management LP Takes Position in Revolution Medicines, Inc. $RVMD

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX, REGN, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

$867.94 +23.44 (+2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$868.42 +0.48 (+0.06%)

As of 06:48 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$92.18 +0.83 (+0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$91.33 -0.85 (-0.92%)

As of 07:01 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Regeneron Pharmaceuticals NASDAQ:REGN

$768.58 +7.92 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$772.80 +4.22 (+0.55%)

As of 07:04 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Revolution Medicines NASDAQ:RVMD

$197.30 +3.84 (+1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$195.65 -1.65 (-0.84%)

As of 07:18 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTX, REGN, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTX, REGN, ARGX, and RVMD Earnings

Compare Dividends

Latest BNTX, REGN, ARGX, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTX, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX, REGN, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

BioNTech NASDAQ:BNTX

Regeneron Pharmaceuticals NASDAQ:REGN

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTX, REGN, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTX, REGN, ARGX, and RVMD Earnings

Compare Dividends

Latest BNTX, REGN, ARGX, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTX, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX, REGN, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

BioNTech NASDAQ:BNTX

Regeneron Pharmaceuticals NASDAQ:REGN

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools